Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,820 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Opioid Use Disorder
Interventions: Youth Opioid Recovery Support (YORS); Behavioral
Lead sponsor: Potomac Health Foundations; Other
Eligibility: 13 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Stress
Interventions: Chaga Mushroom, Algae Extract, Black Cumin Seed Oil, Black Cumin Seed Oil + Astaxanthin, Black Cumin Seed Oil + Omega 3, Placebo; Dietary Supplement
Lead sponsor: 3 Waves Wellness; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Plymouth, Massachusetts

Conditions: Hematopoietic Stem Cell Transplantation, Art Therapy, Physical Therapy
Interventions: Art and Physical Therapy, Physical Therapy; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 5 Years to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Acute Otitis Media, Otitis Media, Ear Infection
Interventions: Montelukast, Placebo; Drug
Lead sponsor: Deborah Gentile; Other
Eligibility: 18 Months to 5 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Bellevue, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: contrast enhanced mammography, Iodinated Contrast Media (ICM); Device · Drug
Lead sponsor: Margarita Louise Zuley; Other
Eligibility: 30 Years and older · Female only
Enrollment: 2,089 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Eating Disorder, Body Image
Interventions: Pride Body Project, Media Advocacy; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Birth Control, Contraception
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 4,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
Interventions: Transoral Surgery, External Beam Radiation Therapy, Cisplatin, Incisional Tumor Biopsy, Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment, MD Anderson Dysphagia Index, University of Washington Quality of Life Questionnaire, Euro-QOL 5 dimension scale questionnaire, Modified barium swallow (MBS) evaluation with aspiration-penetration scale; Procedure · Radiation · Drug + 2 more
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Newark, New Jersey

Conditions: Postpartum Depression, Parenting, Parent-Child Relations
Interventions: Social Media-Based Parenting Program, MoodGym; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Human Abuse Potential
Interventions: Rapastinel, Ketamine, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Community-acquired Pneumonia, Acute Otitis Media, Pharyngitis
Interventions: Quasi experimental intervention; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 26,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more

Conditions: Pain
Interventions: Vapocoolant, Sterile water; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sedentary Lifestyle
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 65 Years
Enrollment: 321 participants
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Concussion, Brain
Interventions: Pre-game Safety Huddles; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 11 Years to 14 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vaccination
Interventions: Vaccine Information Video Dissemination; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes, Type 2
Interventions: Community Health Worker Diabetes Education: Print media, CHW Diabetes Education: tailored web site; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Human Papilloma Virus
Interventions: HPV Educational Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Bradykinesia
Interventions: MSCTC-0010; Biological
Lead sponsor: IMAC Holdings, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Paducah, Kentucky • Chesterfield, Missouri • Brentwood, Tennessee

Conditions: Rheumatoid Arthritis RA
Interventions: Efavaleukin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Anniston, Alabama • Torrance, California • Lansing, Michigan + 2 more

Conditions: Diabetic Foot Ulcers
Interventions: Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle; Drug
Lead sponsor: OcuNexus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more

Conditions: Symmetric Limited Morphea
Interventions: Medium Dose UVA-1, High Dose UVA-1; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Natural Modulators of Immune Function and Mood

Art and Physical Therapy in Pediatric HCT

A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

The Pride Body Project

HER Salt Lake Initiative

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

Social Media-Based Parenting Program for Women With Postpartum Depressive Symptoms

Assessment of Abuse Potential of Rapastinel in Humans

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Vapocoolant (Pain Ease Medium Stream) for Intravenous Lines in Emergency Department Patients

Development and Validation of an Automated Measurement of Child Screen Media Use: FLASH

One Team: Changing the Culture of Youth Sport With Pregame Safety Huddles

Conectados: Social Networks and Social Media for Vaccine Uptake

iDecide.Decido: Diabetes Medication Decision Support Study

Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine

Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.